Partner With Us NRI

Cipla Ltd share Price Today

Company details

6M Return 26.77%
1Y Return 9.78%
Mkt Cap.(Cr) 98,852.91
Volume 2,132,150
Div Yield 0.69%
OI Chg %
Volume 2,132,150

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
US drives growth, outlook for key geographies upbeat
About The Stock

    Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms. Cipla supplies branded and generic medicines to over 170 countries globally.

    • Indian branded formulations business accounts for ~40% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestinal
    • Cipla derives 21% of its export revenues from the US followed by 12% from South Africa, 5% from Europe and 16% from RoW markets

    Numbers were steady and came in better than I-Direct estimates.

    • Sales were up 6% YoY to ₹ 5478.9 crore
    • EBITDA in Q3FY22 was flat YoY at ₹ 1231 crore, with margins at 22.5%
    • Consequent adjusted PAT was at ₹ 728.6 crore (down 2.6% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Cipla announced Q2FY24 results:

1. Financial Performance:
- Cipla achieves highest ever quarterly revenue of Rs 6,678 crore, a 14.6% YoY increase.
- EBITDA margin reaches a record 26% at Rs 1,734 crore, a 33.1% YoY growth.
- PAT stands at Rs 1,131 crore, a significant 43.4% YoY increase.
- R&D investments increased by 13% YoY, totaling Rs 379 crore or 5.7% of sales.
- Strong balance sheet health continues with a robust net cash position of Rs 5,850 crore.

2. One-India Business:
- One-India business records a 10% YoY growth, driven by strong performance in Branded Prescription and Trade Generics.
- Branded Prescription grows at 11% YoY, outperforming the market.
- Trade Generics achieve double-digit growth despite weak seasonality, aided by declining raw material costs.
- Consumer Health sees improvement, with chronic share increasing by 140 bps YoY to 60%.

3. North America:
- North America business reaches a quarterly revenue of USD 229 million, growing by 28% YoY.
- Market share expands across key differentiated assets, with Lanreotide's market share at 20%.
- Strong traction and share expansion in core products drive the growth in North America.

4. South Africa:
- The private Market in South Africa grows at 12% YoY in local currency terms, outpacing the overall market.
- Robust performance in prescription and OTC contributes to the growth.
- Acquisition of Actor expected to expand OTC share.

Umang Vohra, MD and Global CEO, Cipla said, "Pleased to share an exceptional set of results reflecting the strength of our core business across key markets of India, North America, and South Africa. We reported our highest-ever quarterly revenue with EBITDA margins scaling up to 26%. One-India business grew at a healthy 10% YoY with continued market-beating performance in the branded prescription and Trade Generics business. In South Africa, the private market business grew in double digits driven by strong execution across prescription and OTC. The North America business scaled up to USD 229 million, growing 28% YoY, driven by strong traction across core products with share expansion in differentiated assets. Our pipeline is progressing well with key milestones achieved in Respiratory and Peptide assets. We will continue our focus on driving profitable growth across businesses"



Result PDF

View Other Company Results


Investment recommendation
US drives growth, outlook for key geographies upbeat
Call Date
13 May 2023
Entry Price 935.00
Target Price 1,090.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Cipla Ltd Stocks COMPARISION


Equity Capital: 24,638.09 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 18,627.88 33,461.81
LAST 3M 55,364.88 13,143.97
LAST 6M 96,704.70 86,889.39
LAST 12M 161,735.00 130,136.85
Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Dec 04, 2023 l NSE Announcement

Cipla Limited - Loss of Share Certificates

Nov 30, 2023 l NSE Announcement

Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Nov 29, 2023 l NSE Announcement

Date Action Type Ratio
Jul 21, 2023 Dividend 425
Aug 08, 2022 Dividend 250
Aug 09, 2021 Dividend 250

Cipla Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Cipla Limited is a pharmaceutical company having a market capitalization of Rs. 73,307.57 crores as of 18th August 2021. The company was incorporated within the year 1935. It reported its consolidated revenue at Rs. 5,504.35 for the quarter ended June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 500087 and scrip code CIPLA, respectively. As of 18th August 2021, the shares of Cipla were trading at Rs. 908.85.

    Cipla is headquartered in Mumbai and produces products for various therapeutic areas, including cardiology, children’s health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious illnesses & critical care, malaria, and so on. The drug company primarily develops medicines to treat respiratory, disorders, arthritis, diabetes, weight control and depression, and other medical conditions. Cipla is the third-largest drug company within the country and is present in most countries within the European region, with DTMs in Germany, Norway, UK, and Spain. The company’s promoters hold a 36.72% stake of the total shareholding in the company in June 2021 as against 36.68% in June 2020 with zero pledge. However, the mutual funds holding has also decreased in the last 12 months, decreasing from 16.29% in June 2020 to 13.36% in June 2021, and over the last 3 months, it has decreased 1.28%.

    In June 2021, consolidated total revenue from operations grew 26.64% to Rs. 5,504.35 crores, against Rs. 4,346.16 crores within the corresponding quarter last year. The Indian major pharmaceutical has posted a 23.67% increase in the consolidated net profit of Rs. 714.72 crores, on strong sales performance during June 2021, it had posted a net profit of Rs. 577.91 Crores within the corresponding period of the previous fiscal. EBITDA rose 28% to Rs. 1,346 crores in June 2021, from Rs. 1,049 crores in June 2020. EBITDA margin improved 32 basis points to 24.5%, as against 24.1% in the year-ago period. EPS of the company was Rs. 8.86 as compared to Rs. 5.13 in March 2021. Cipla’s shares closed at 908.85 (NSE) on 18th August 2021 and have returned 18.83% over the last 12 months.

Registered Address

Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013

Tel : 91-22-24826000
Email : cosecretary:cipla.com
Website : http://www.cipla.com

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500087
Book Closure Date (Month) :
BSE Group : A
ISIN : INE059A01026

FAQ’s on Cipla Ltd Shares

You can buy Cipla Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Cipla Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 05, 2023 03:59 PM the closing price of Cipla Ltd was ₹ 1,224.45.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 05, 2023 03:59 PM, the market cap of Cipla Ltd stood at ₹ 98,852.91.

The latest PE ratio of Cipla Ltd as of Dec 05, 2023 03:59 PM is 27.78

The latest PB ratio of Cipla Ltd as of Dec 05, 2023 03:59 PM is 0.25

The 52-week high of Cipla Ltd is ₹ 1,283.55 while the 52-week low is ₹ 852.00

According to analyst recommendations, Cipla Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app